The treatment of light-chain (AL) amyloidosis is directed against the plasma cells that produce the light-chain forming the amyloid deposits. The plasma cells can be killed and their growth can be stopped by drugs used in chemotherapy, such as cyclophosphamide, steroids, such as dexamethasone, and drugs that stimulate the immune system, such as lenalidomide. The present trial studies the efficacy and safety of the combination of cyclophosphamide, lenalidomide and dexamethasone in patients with AL amyloidosis who were previously treated and need further therapy.
Name: cyclophosphamide
Description: cyclophosphamide: 500 mg orally on days 1, 8, 15Type: Drug1
Name: lenalidomide
Description: lenalidomide: 15 mg orally on days 1-21Type: Drug1
Name: dexamethasone
Description: dexamethasone: 40 mg orally on days on days 1, 8, 15, 22Type: Drug1
Single Group Assignment
There is one SNP
Prior diagnosis of antiphospholipid antibodies or lupus anticoagulant, factor V Leiden mutation, prothrombin G21210A mutation, antithrombin, protein C or S deficiency. --- G21210A ---